EXEL

ExelixisA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

Probability

Target price

$56.00

+15.4% vs current

Most likely

Base case

Probability

Target price

$48.00

-1.1% vs current

B-

Bear case

Probability

Target price

$39.00

-19.7% vs current

AI sentiment snapshot

Latest data as of 2026-05-08

AI commentary

Sentiment is constructive but not emphatic. Primary-source earnings materials were supportive, and delayed sell-side reaction was directionally positive via multiple target raises. Market reaction was mixed: EXEL closed at $44.42 on May 5, jumped to $48.70 on May 6 (+9.6%), then retraced to $46.21 on May 7 (-5.1%); on May 8 it traded around $47.73 intraday. That pattern fits a monitoring thesis where investors accept the earnings quality and pipeline cadence, but still want more proof before paying materially above consensus target levels. Social-context coverage was not provided, so confidence rests mainly on filings, the earnings release, and trusted market-source follow-up.

RankAlpha Sentiment Codex - 2026-05-08

Open post-earnings memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-31catalystPost-earnings execution and capital return follow-throughMedium impact

Q1 total revenue rose to $610.8 million and net product revenue to $555.0 million, Exelixis maintained 2026 revenue guidance, and the board authorized an additional $750 million repurchase through 2027; several post-print target raises followed, including Morgan Stanley to $50, Stifel to $47, TD Cowen to $55, and H.C. Wainwright to $56 [#8-K-2026-05-05] [#10-Q-2026-05-05].

2026-12-03eventZanzalintinib mCRC FDA reviewHigh impact

Management said the first zanzalintinib NDA, for previously treated metastatic colorectal cancer in combination with atezolizumab, is under active U.S. review with a target action date of December 3, 2026 [#8-K-2026-05-05].

2026-12-31catalyst2026 zanzalintinib readout cadenceHigh impact

Exelixis guided to key 2026 pipeline milestones including STELLAR-303 and STELLAR-304 data, enrollment progress in STELLAR-311, and initiation of STELLAR-316, while also adding STELLAR-202 and a new STELLAR-002 expansion cohort [#8-K-2026-05-05].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-08 • Updated nightlySource: Internal modelMethodology